Windlas Biotech, Mateon Therapeutics launch integrated solution for respiratory wellness in India
Mateon Therapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
Zacks Small-Cap Research
A Covid-19 treatment plan slowly emerges | Evaluate
Keeping an eye on Mateon Therapeutics (OTCQB: MATN) says GEN - Genetic Engineering & Biotechnology News - EmergingGrowth.com
FinData: Share Price for NASDAQ, MATN - Mateon Therapeutics Inc.
MATN: Positive Early Results for ARTIVeda™ in Treating COVID-19…
About Us – Oncotelic
Consulting Agreement by and between the Company and Artius, | MATEON THERAPEUTICS INC | Business Contracts | Justia
Mateon and PointR to merge into AI-driven oncology firm
Mateon Therapeutics (MATN) expands its management team to accelerate the commercialization and development of OT-101 for COVID-19 - EmergingGrowth.com
Joint Venture Agreement relating to GMP Biotechnology Limited | MATEON THERAPEUTICS INC | Business Contracts | Justia
Windlas Biotech and Mateon Therapeutics Launch India's First Combined Lung Therapy and Ai Telemedicine 360 Solution to Transform Respiratory Wellness - The Pharma Times | Pharma & Health Care News Portal
EDGAR Filing Documents for 0001493152-21-001207
Mateon Therapeutics
Mateon Therapeutics - BIO Investor Forum | BIO
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
Mateon Therapeutics Archives - IndiaMedToday
Windlas Biotech and Mateon Therapeutics launch first-ever Drug-Device Lung Therapy Combined AI 360 platform for respiratory wellness - The Statesman
MATEON'S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST